TRC160334（Cat No.:I037468）is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF-α subunits, enhancing transcription of genes involved in erythropoiesis, angiogenesis, and cellular adaptation to hypoxia. By preventing HIF-α degradation, TRC160334 boosts endogenous erythropoietin production and improves oxygen delivery. Preclinical studies suggest protective effects in ischemia–reperfusion injury, anemia, and inflammatory conditions. Its oral bioavailability and favorable pharmacokinetic profile make it a valuable research tool for exploring hypoxia signaling, tissue protection, and therapeutic strategies targeting anemia and ischemic disorders through modulation of the HIF pathway.